EGFR and central nervous system cancer: We show that ANC@RNP/crEGFR‐PLK1 nanomedicine mediated efficient dual gene targeting of EGFR and PLK1 oncogenes in glioma cells with enhanced anti‐tumor effect versus single crRNA targeting of oncogenes.